These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
408 related articles for article (PubMed ID: 9513720)
1. Use of mouse mammary tumour virus (MMTV)/neu transgenic mice to identify genes collaborating with the c-erbB-2 oncogene in mammary tumour development. Jolicoeur P; Bouchard L; Guimond A; Ste-Marie M; Hanna Z; Dievart A Biochem Soc Symp; 1998; 63():159-65. PubMed ID: 9513720 [TBL] [Abstract][Full Text] [Related]
2. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis. Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418 [TBL] [Abstract][Full Text] [Related]
3. MMTV promoter hypomethylation is linked to spontaneous and MNU associated c-neu expression and mammary carcinogenesis in MMTV c-neu transgenic mice. Zhou H; Chen WD; Qin X; Lee K; Liu L; Markowitz SD; Gerson SL Oncogene; 2001 Sep; 20(42):6009-17. PubMed ID: 11593408 [TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo antisense-mediated growth inhibition of a mammary adenocarcinoma from MMTV-neu transgenic mice. Sacco MG; Barbieri O; Piccini D; Noviello E; Zoppé M; Zucchi I; Frattini A; Villa A; Vezzoni P Gene Ther; 1998 Mar; 5(3):388-93. PubMed ID: 9614559 [TBL] [Abstract][Full Text] [Related]
5. Rassf3 is responsible in part for resistance to mammary tumor development in neu transgenic mice. Jacquemart IC; Springs AE; Chen WY Int J Oncol; 2009 Feb; 34(2):517-28. PubMed ID: 19148488 [TBL] [Abstract][Full Text] [Related]
6. Identification of tumorsphere- and tumor-initiating cells in HER2/Neu-induced mammary tumors. Liu JC; Deng T; Lehal RS; Kim J; Zacksenhaus E Cancer Res; 2007 Sep; 67(18):8671-81. PubMed ID: 17875707 [TBL] [Abstract][Full Text] [Related]
8. Induction of a variety of preneoplasias and tumours in the mammary glands of transgenic rats. Davies BR; Warren JR; Schmidt G; Rudland PS Biochem Soc Symp; 1998; 63():167-84. PubMed ID: 9513721 [TBL] [Abstract][Full Text] [Related]
9. Lack of ductal development in the absence of functional estrogen receptor alpha delays mammary tumor formation induced by transgenic expression of ErbB2/neu. Hewitt SC; Bocchinfuso WP; Zhai J; Harrell C; Koonce L; Clark J; Myers P; Korach KS Cancer Res; 2002 May; 62(10):2798-805. PubMed ID: 12019156 [TBL] [Abstract][Full Text] [Related]
10. Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53, and mouse mammary tumor virus. Zelazny E; Li B; Anagnostopoulos AM; Coleman A; Perkins AS Exp Mol Pathol; 2001 Jun; 70(3):183-93. PubMed ID: 11417997 [TBL] [Abstract][Full Text] [Related]
11. Somatic mutations that contribute to breast cancer. Callahan R Biochem Soc Symp; 1998; 63():211-21. PubMed ID: 9513725 [TBL] [Abstract][Full Text] [Related]
12. Involvement of Notch1 in the development of mouse mammary tumors. Diévart A; Beaulieu N; Jolicoeur P Oncogene; 1999 Oct; 18(44):5973-81. PubMed ID: 10557086 [TBL] [Abstract][Full Text] [Related]
13. Challenge with mammary tumor cells expressing MHC class II and CD80 prevents the development of spontaneously arising tumors in MMTV-neu transgenic mice. Jabrane-Ferrat N; Campbell MJ; Esserman LJ; Peterlin BM Cancer Gene Ther; 2006 Nov; 13(11):1002-10. PubMed ID: 16841083 [TBL] [Abstract][Full Text] [Related]
14. Transgenic mice with mammary gland targeted expression of human cortactin do not develop (pre-malignant) breast tumors: studies in MMTV-cortactin and MMTV-cortactin/-cyclin D1 bitransgenic mice. van Rossum AG; van Bragt MP; Schuuring-Scholtes E; van der Ploeg JC; van Krieken JH; Kluin PM; Schuuring E BMC Cancer; 2006 Mar; 6():58. PubMed ID: 16536875 [TBL] [Abstract][Full Text] [Related]
15. Induction of epithelial abnormalities that resemble human breast lesions by the expression of the neu/erbB-2 oncogene in reconstituted mouse mammary gland. Bradbury JM; Arno J; Edwards PA Oncogene; 1993 Jun; 8(6):1551-8. PubMed ID: 8099220 [TBL] [Abstract][Full Text] [Related]
16. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Howe LR; Subbaramaiah K; Patel J; Masferrer JL; Deora A; Hudis C; Thaler HT; Muller WJ; Du B; Brown AM; Dannenberg AJ Cancer Res; 2002 Oct; 62(19):5405-7. PubMed ID: 12359744 [TBL] [Abstract][Full Text] [Related]
17. Maspin expression inversely correlates with breast tumor progression in MMTV/TGF-alpha transgenic mouse model. Reddy KB; McGowen R; Schuger L; Visscher D; Sheng S Oncogene; 2001 Oct; 20(45):6538-43. PubMed ID: 11641778 [TBL] [Abstract][Full Text] [Related]
18. Mouse mammary tumor virus p75 and p110 CUX1 transgenic mice develop mammary tumors of various histologic types. Cadieux C; Kedinger V; Yao L; Vadnais C; Drossos M; Paquet M; Nepveu A Cancer Res; 2009 Sep; 69(18):7188-97. PubMed ID: 19738070 [TBL] [Abstract][Full Text] [Related]
19. Fgf10 is an oncogene activated by MMTV insertional mutagenesis in mouse mammary tumors and overexpressed in a subset of human breast carcinomas. Theodorou V; Boer M; Weigelt B; Jonkers J; van der Valk M; Hilkens J Oncogene; 2004 Aug; 23(36):6047-55. PubMed ID: 15208658 [TBL] [Abstract][Full Text] [Related]
20. Tamoxifen chemoprevention of a hormone-independent tumor in the proto-neu transgenic mice model. Ménard S; Aiello P; Tagliabue E; Rumio C; Lollini PL; Colnaghi MI; Balsari A Cancer Res; 2000 Jan; 60(2):273-5. PubMed ID: 10667575 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]